Linezolid treatment for osteomyelitis due to Staphylococcus Epidermidis with reduced vancomycin susceptibility

Journal of Korean Neurosurgical Society

Volumn 43, Issue 6, 2008, Pages 307-310

  Nam, Joan Rek ^a   Kim, Myoung Soo ^a   Lee, Chae Hauck ^a   Whang, Dong Hee ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Linezolid; Skull osteomyelitis; Staphylococcus epidermidis; Vancomycin resistance

Indexed keywords

LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BLOOD CULTURE; BRAIN HEMORRHAGE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DYSPHASIA; GENERAL CONDITION DETERIORATION; HEADACHE; HUMAN; LEFT HEMISPHERE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NEUROIMAGING; OSTEOMYELITIS; PENICILLIN RESISTANCE; SCALP; SKULL DISEASE; STAPHYLOCOCCUS EPIDERMIDIS; SUBDURAL HEMATOMA; WOUND INFECTION;

EID: 51449099949     PISSN: 12258245     EISSN: 15987876     Source Type: Journal    
DOI: 10.3340/jkns.2008.43.6.307     Document Type: Article

References (14)

1. Bodogan B, Appelbaum PC: Oxazolidinones: activitiy, mode of action, and mechanism of resistance. Int J Antimicrob Agents 23: 113-119, 2004
2. Davenport DS, Massanari RM, Pfaller MA, Bale MJ, Streed SA, Hierholzer WJ Jr: Usefulness of a test for slime production as a marker for clinically significant infections with coagulase-negative staphylococci. J Infect Dis 153: 332-339, 1986
3. Dunne WM Jr, Qureshi H, Pervez H, Nafziger DA: Staphylococcus epidermidis with intermediate resistance to vancomycin: elusive phenotype or laboratory artifact? Clin Infect Dis 33: 135-137, 2001
4. Farber BF, Kaplan MH, Cloqston AG: Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis 161: 37-40, 1990
5. Garrett DO, Jochimsen E, Murfitt K, Hill B, McAllister S, Nelson P, et al: The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 20: 167-170, 1999
6. Kaatz GW, Seo SM: In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 40: 799-801, 1996
7. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM: Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 50: 747-750, 2002
8. Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ: Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 32: 8-14, 2004
9. Schwalbe RS, Ritz WJ, Verma PR, Barranco EA, Gilligan PH: Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis 161: 45-51, 1990
10. Schwalbe RS, Stapleton JT, Gilliqan PH: Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 316: 927-931, 1987
11. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et al: Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 36: 1020-1027, 1988
12. Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP: Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 28: 2064-2068, 1990
13. Wong SS, Ho PL, Woo PC, Yuen KY: Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 29: 760-767, 1999
14. Woodford N, Johnson AP, George RC: Detection of glycopeptide resistance in clinical isolates of gram-positive bacteria. J Antimicrob Chemother 28: 483-486, 1991